Sugi Predict

Sugi Predict / Compounds / SCHEMBL2214871

SCHEMBL2214871

SCHEMBL2214871

O=Cc1cc(Br)cnc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 6/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MPI P34949 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TRIM24 O15164 1/20 0.35
▸ TRIM33 Q9UPN9 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ PLAU P00749 1/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.33
▸ ALPL P05186 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30326046 1.00 ERN1 (0.39) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL23457225 0.79 HTT (0.34) KMT2ASMN1; SMN2HTTPLAUALPL
SCHEMBL15052994 0.78 TRIM24 (0.47) ERN1ALDH1A1KMT2ATRIM24TRIM33
SCHEMBL6076848 0.78 ERN1 (0.46) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30129411 0.78 ERN1 (0.46) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29952839 0.77 CYP1A2 (0.39) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL8544546 0.77 CYP1A2 (0.39) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL28518576 0.77 ERN1 (0.41) ERN1ALDH1A1KMT2ATRIM24TRIM33
SCHEMBL2119952 0.75 ERN1 (0.39) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2851214 0.75 ALDH1A1 (0.47) ERN1CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113214182-B Benzisothiazole compound and preparation method thereof 佛山湘潭大学绿色智造研究院 2022-12-23 — — CN claimed
CN-113214182-A Benzisothiazole compound and preparation method thereof 佛山湘潭大学绿色智造研究院 2021-08-06 — — CN claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
WO-2026090300-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
EP-4698544-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2026-02-25 — — EP disclosed
US-12459927-B2 Plasma kallikrein inhibitors MERCK SHARP & DOHME LLC (US) 2025-11-04 — — US disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 — — US disclosed
EP-4565589-A2 OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF Icahn School of Medicine at Mount Sinai (US) 2025-06-11 — — EP disclosed
CN-115867556-B LPA receptor antagonists and uses thereof 吉利德科学公司 2025-05-06 — — CN disclosed
CN-101068797-A Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof MITSUBISHI PHARMA CORP (JP) 2007-11-07 — — CN disclosed
US-7288654-B2 Fused-ring pyridine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LTD (JP) 2007-10-30 — — US disclosed
US-20060178359-A1 Tricyclic compound, process for producing the same, and use SYNGENTA CROP PROTECTION AG (CH) 2006-08-10 — — US disclosed
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-20 — — US disclosed
US-20060100197-A1 Fused-ring pyridine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-05-11 — — US disclosed
EP-1593681-A1 TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed
EP-1593680-A1 FUSED-RING PYRIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed
EP-1593673-A1 ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed
CN-1178939-C Non-nucleoside reverse transcriptase inhibitors ���ָ����Ӣ��ķ���ô����޹�˾ 2004-12-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use CCR5, MSR1, CCR2 ERN1 1319/4885CYP1A2 362/4885CYP3A4 416/4885
US-20060178359-A1 Tricyclic compound, process for producing the same, and use CCR4, CCR5, CCR1 ERN1 997/4885CYP1A2 987/4885CYP3A4 127/4885
US-12459927-B2 Plasma kallikrein inhibitors KLKB1, SERPINE1, KLK5 ERN1 2190/4885CYP1A2 2491/4885CYP3A4 2398/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 ERN1 325/4885CYP1A2 3089/4885CYP3A4 2504/4885
US-20060100197-A1 Fused-ring pyridine derivative, process for producing the same, and use CCR5, CXCR4, CCR4 ERN1 2299/4885CYP1A2 760/4885CYP3A4 90/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 ERN1 2882/4885CYP1A2 3194/4885CYP3A4 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.